Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck and Intercell said that the independent Data Monitoring Committee (DMC) has recommended to suspend the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S aureus) infection.
Subscribe to our email newsletter
The decision has been taken by DMC following a pre-specified interim analysis from the Phase II and III clinical trial.
The partners said the trial did not meet the pre-specified futility criteria and further analysis of the benefit-risk of the vaccine candidate will be initiated.
S. aureus causes hospital-acquired infections and 50% of strains isolated in hospitals globally are resistant to antibiotics.